These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19632957)

  • 1. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.
    Redhage LA; Shintani A; Haas DW; Emeagwali N; Markovic M; Oboho I; Mwenya C; Erdem H; Acosta EP; Morrow JD; Hulgan T
    HIV Clin Trials; 2009; 10(3):181-92. PubMed ID: 19632957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidant stress is increased during treatment of human immunodeficiency virus infection.
    Hulgan T; Morrow J; D'Aquila RT; Raffanti S; Morgan M; Rebeiro P; Haas DW
    Clin Infect Dis; 2003 Dec; 37(12):1711-7. PubMed ID: 14689356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
    Madden E; Lee G; Kotler DP; Wanke C; Lewis CE; Tracy R; Heymsfield S; Shlipak MG; Bacchetti P; Scherzer R; Grunfeld C
    AIDS; 2008 Mar; 22(6):707-15. PubMed ID: 18356600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
    Loutfy MR; Walmsley SL; Klein MB; Raboud J; Tseng AL; Blitz SL; Pick N; Conway B; Angel JB; Rachlis AR; Gough K; Cohen J; Haase D; Burdge D; Smaill FM; de Pokomandy A; Loemba H; Trottier S; la Porte CJ
    BMC Infect Dis; 2013 Jun; 13():256. PubMed ID: 23732043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher serum iron is associated with increased oxidant stress in HIV-infected men.
    Crist MB; Melekhin VV; Bian A; Shintani A; Milne GL; Kallianpur AR; Dageforde LA; Haas DW; Hulgan T
    J Acquir Immune Defic Syndr; 2013 Dec; 64(4):367-73. PubMed ID: 24169121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
    Gupta SK; Shen C; Moe SM; Kamendulis LM; Goldman M; Dubé MP
    PLoS One; 2012; 7(9):e45716. PubMed ID: 23029197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
    Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
    J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
    Ma Q; Zingman BS; Luque AE; Fischl MA; Gripshover BM; Venuto CS; DiFrancesco R; Forrest A; Morse GD
    Ther Drug Monit; 2011 Jun; 33(3):309-14. PubMed ID: 21544014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.
    Karamchand S; Leisegang R; Schomaker M; Maartens G; Walters L; Hislop M; Dave JA; Levitt NS; Cohen K
    Medicine (Baltimore); 2016 Mar; 95(9):e2844. PubMed ID: 26945366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.
    Ikizler TA; Morrow JD; Roberts LJ; Evanson JA; Becker B; Hakim RM; Shyr Y; Himmelfarb J
    Clin Nephrol; 2002 Sep; 58(3):190-7. PubMed ID: 12356187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.